A Study of TL-925 as a Treatment for Dry Eye Disease
Launched by TELIOS PHARMA, INC. · Feb 22, 2023
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals aged 18 years or older
- • A diagnosis of dry eye disease for at least 6 months
- • An unanesthetized Schirmer's test score (STS) of ≤ 10mm and ≥ 1mm in the study eye
- • A tear film break-up time (TFBUT) of ≤ 5 seconds in the study eye
- • A corneal fluorescein staining score of ≥ 2 in at least one region of the cornea
- • A sum corneal fluorescein staining score of ≥ 4 in the study eye
- • A total lissamine green conjunctival score of ≥ 2 in the study eye
- • Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
- Exclusion Criteria:
- • Any clinically significant slit lamp finding
- • Any ongoing ocular infection (bacterial, viral or fungal) or active ocular inflammation
- • Any keratorefractive surgery within the last 12 months
- • Any intraocular or extraocular surgery within 3 months
About Telios Pharma, Inc.
Telios Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs in the field of dermatology and other specialty areas. With a commitment to advancing patient care, Telios leverages cutting-edge scientific research and a robust pipeline of product candidates aimed at addressing conditions characterized by inflammation and tissue repair. The company’s mission is to transform the standard of care through the discovery and development of novel treatments that enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Andover, Massachusetts, United States
Colorado Springs, Colorado, United States
Newport Beach, California, United States
Indianapolis, Indiana, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials